Bicycle Therapeutics Stock Forecast
NASDAQ: BCYCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
BCYC analyst consensus
Consensus (9 analysts)
none
Avg. price target
$9.50+149.34%
- Strong buy 2
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering Bicycle Therapeutics (2026-10-08), 6 rate the stock a buy or strong buy, 3 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $9.50, with a high estimate of $14.00 and a low estimate of $5.00. The average target implies upside of 149.3% from the current price of $3.81.
The spread between the highest and lowest targets is 180.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BCYC.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 22% |
| Buy | 4 | 44% |
| Hold | 3 | 33% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.00 | +31.23% |
| Average target | $9.50 | +149.34% |
| High target | $14.00 | +267.45% |